{"schema_version":"secwatch.filing_event.v1","accession":"0001823239-26-000049","form_type":"8-K","ticker":"MRVI","cik":"0001823239","company_name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","filed_at":"2026-06-03T12:31:58+00:00","discovered_at":"2026-06-03T12:35:00.552074+00:00","generated_at":"2026-06-03T12:35:12.951149+00:00","sec_items":["1.01","1.02","2.03","7.01","9.01"],"event_type":"debt","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Maravai LifeSciences refinances credit agreement, reduces debt by ~$93M and extends maturity to 2032","bullets":["New $150M term loan and $30M revolver mature June 2032; proceeds plus $98.5M cash repaid $242.9M prior debt due Oct 2027.","Interest rate at Term SOFR + 5.00% (stepdown to 4.75% if first lien net leverage ≤ 3.0x).","Financial covenant (max 6.5x leverage) applies only if revolver usage exceeds 40% of $30M commitment.","Net debt reduced from $242.9M to $150.0M; revolver provides $30M additional liquidity.","CFO Raj Asarpota cited strengthened financial foundation and preserved access to capital for growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001823239-26-000049","json":"https://secwatch.observer/filing/0001823239-26-000049.json","markdown":"https://secwatch.observer/filing/0001823239-26-000049.md","text":"https://secwatch.observer/filing/0001823239-26-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/0001823239-26-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/mrvi-20260602.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T12:35:12.951149+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bac57d5e345ee5916b1aa4c80029294f36819c72","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. incurred term loan of $150.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.","evidence_excerpt":"On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/0001823239-26-000049-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"term loan"},{"label":"Principal","value":"$150.0 million"},{"label":"Counterparty","value":"BSP Agency, LLC"},{"label":"Rate","value":"Term SOFR plus 5.00% per annum"},{"label":"Maturity","value":"June 2, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"d63f4907a00d8440d76303a9899ae6bc6554da23","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. incurred revolving credit of $30.0 million with BSP Agency, LLC at Term SOFR plus 5.00% per annum maturing June 2, 2032.","evidence_excerpt":"On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent. The New Credit Agreement provides the Borrower with a $150.0 million term loan facility (the “New Term Loan”) and a $30.0 million revolving credit facility (the “New Revolving Credit Facility”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/0001823239-26-000049-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"revolving credit"},{"label":"Principal","value":"$30.0 million"},{"label":"Counterparty","value":"BSP Agency, LLC"},{"label":"Rate","value":"Term SOFR plus 5.00% per annum"},{"label":"Maturity","value":"June 2, 2032"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"13d45313c37be24eea97c699eeb5410e404f52f7","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. terminated Prior Credit Agreement with Morgan Stanley Senior Funding, Inc. (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, the parties terminated the Prior Credit Agreement in connection with the Borrower’s prepayment in full of all outstanding borrowings and accrued interest thereunder.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/0001823239-26-000049-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"termination"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Morgan Stanley Senior Funding, Inc."},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"},{"claim_id":"85b3b1e0d6ce324f4dea85b3c77ac089b92ad38b","claim":"MARAVAI LIFESCIENCES HOLDINGS, INC. entered into New Credit Agreement with certain lenders and issuing banks valued at $150.0 million term loan facility and a $30.0 million revolving credit facility (effective 2026-06-02).","evidence_excerpt":"On June 2, 2026, Maravai Intermediate Holdings, LLC (the “Borrower”) and Maravai Topco Holdings, LLC (“Topco”), each a consolidated subsidiary controlled by Maravai LifeSciences Holdings, Inc., entered into a Credit Agreement (the “New Credit Agreement”) with certain lenders and issuing banks party thereto and BSP Agency, LLC, as administrative agent and collateral agent.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323926000049/0001823239-26-000049-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"certain lenders and issuing banks"},{"label":"Value","value":"$150.0 million term loan facility and a $30.0 million revolving credit facility"},{"label":"Effective","value":"2026-06-02"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}